サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1641778

グルカゴンの世界市場：製品タイプ別、用途別、流通チャネル別 - 機会分析と産業予測、2024年～2033年

Glucagon Market By Product Type , By Application By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2024-2033

出版日
ページ情報
英文 216 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
グルカゴンの世界市場：製品タイプ別、用途別、流通チャネル別 - 機会分析と産業予測、2024年～2033年
出版日: 2024年12月01日
発行: Allied Market Research
ページ情報: 英文 216 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

グルカゴン市場は2023年に3億米ドルとなり、2024年から2033年までのCAGRは6.4%で、2033年までには6億米ドルに達すると予測されています。

Glucagon Market-IMG1

グルカゴンは、膵臓のα細胞で産生されるペプチドホルモンです。血糖値が下がりすぎたときに血糖値を上昇させ、体内のエネルギーバランスを維持することで、ブドウ糖代謝に重要な役割を果たしています。このホルモンは主に肝臓に作用し、グリコーゲンの分解（グリコーゲン分解）を促進し、非炭水化物源からのグルコースの産生（糖新生）を刺激します。グルカゴンは血糖値を下げるインスリンに対抗して働きます。

糖尿病、特に1型糖尿病の世界の罹患率の憂慮すべき上昇は、重度の低血糖を管理するための重要な治療法であるため、グルカゴンの需要を牽引しています。国際糖尿病連合（2023年）は、5億4,000万人以上の成人が世界的に糖尿病を患っていると推定しており、グルカゴン治療の重要性を強調しています。さらに、低血糖管理に関するヘルスケア組織による教育的取り組みにより、特に重症低血糖エピソードのリスクが高い糖尿病患者の間でグルカゴン製剤の採用が増加しています。さらに、高齢者人口の急増が世界市場の主要な推進力となっています。世界人口の高齢化に伴い、糖尿病および関連合併症のリスクを抱える人が増加しており、グルカゴン製品の需要を牽引しています。世界保健機関（WHO）が発表した2024年の調査では、高齢者の数が2020年の10億人から、2030年までには14億人に増加することが明らかになりました。さらに、80歳以上の高齢者数は2050年までに4億2,600万人に達すると推定されています。さらに、グルカゴンは低血糖症への使用だけでなく、消化管を弛緩させるための画像診断（放射線検査や内視鏡検査など）への採用も増えており、その市場範囲は広がっています。しかし、グルカゴン療法、特に経鼻グルカゴンのような新しい製剤は高価であるため、特に低所得地域や十分なヘルスケア保険がない患者にとっては、アクセスの大きな障壁となり得ます。グルカゴンの使用、特に緊急時の使用には、通常、適切な投与のためにヘルスケア専門家の指導が必要であり、医療支援をすぐに受けられない状況での使用がさらに制限される可能性があります。一方、プレフィルドシリンジ、自動注射器、経鼻グルカゴン製剤などの技術革新により、投与が容易になり、患者や介護者にとってグルカゴン療法がより身近で使いやすいものとなっています。このような開発は、予測期間中に世界市場拡大の新たな道を開くと予想されます。

世界のグルカゴン産業は、タイプ、用途、流通チャネル、地域に区分されます。タイプ別では、市場は注射用グルカゴンと経鼻用グルカゴンに分類されます。用途別では、低血糖症と診断補助に分別されます。流通チャネル別では、病院薬局、小売薬局、オンライン薬局に細分化されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカで分析されます。

主要な調査結果

タイプ別では、注射用グルカゴンが2024年から2033年にかけて市場を独占すると予測されます。

用途別では、低血糖症分野が予測期間中に世界市場の成長を示すと予測されます。

流通チャネル別では、病院薬局セグメントが予測期間を通じて顕著なペースで成長すると予測されます。

地域別では、グルカゴン市場は北米で力強い成長が見込まれます。

本レポートのカスタマイズが可能です。（追加費用とスケジュールがあります。）

  • 規制ガイドライン
  • クライアントの関心に応じた企業プロファイルの追加
  • 企業プロファイルの拡張リスト
  • 償還シナリオ

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要な調査結果
    • 主要な投資機会
    • 主要な成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 グルカゴン市場：製品タイプ別

  • 市場概要
  • 注射グルカゴン
  • 経鼻グルカゴン

第5章 グルカゴン市場：用途別

  • 市場概要
  • 低血糖症
  • 診断補助

第6章 グルカゴン市場：流通経路別

  • 市場概要
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 グルカゴン市場：地域別

  • 市場概要
  • 北米
    • 主要な市場動向と機会
    • 米国のグルカゴン市場
    • カナダのグルカゴン市場
    • メキシコのグルカゴン市場
  • 欧州
    • 主要な市場動向と機会
    • フランスのグルカゴン市場
    • ドイツのグルカゴン市場
    • イタリアのグルカゴン市場
    • スペインのグルカゴン市場
    • 英国のグルカゴン市場
    • その他欧州のグルカゴン市場
  • アジア太平洋
    • 主要な市場動向と機会
    • 中国のグルカゴン市場
    • 日本のグルカゴン市場
    • インドのグルカゴン市場
    • 韓国のグルカゴン市場
    • オーストラリアのグルカゴン市場
    • その他アジア太平洋のグルカゴン市場
  • ラテンアメリカ、中東・アフリカ
    • 主要な市場動向と機会
    • ブラジルのグルカゴン市場
    • 南アフリカのグルカゴン市場
    • サウジアラビアのグルカゴン市場
    • その他のラテンアメリカ、中東・アフリカのグルカゴン市場

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング、2023年

第9章 企業プロファイル

  • Novo Nordisk A/S
  • Fresenius SE And Co. KGaA
  • Amphastar Pharmaceuticals, Inc.
  • Xeris Biopharma Holdings, Inc.
  • ILS Inc
  • United Biotech（P）Limited
  • Zealand Pharma A/S
  • Taj Pharmaceuticals Limited
  • Eli Lilly And Company.
  • Pfizer Inc.
目次
Product Code: A324426

The glucagon market was valued at $0.3 billion in 2023, and is projected to reach $0.6 billion by 2033, growing at a CAGR of 6.4% from 2024 to 2033.

Glucagon Market - IMG1

Glucagon is a peptide hormone produced by the alpha cells of the pancreas. It plays a critical role in glucose metabolism by increasing blood glucose levels when they drop too low, thus maintaining energy balance in the body. This hormone primarily acts on the liver, promoting glycogen breakdown (glycogenolysis) and stimulating the production of glucose from non-carbohydrate sources (gluconeogenesis). Glucagon works in opposition to insulin, which lowers blood glucose levels.

Alarming rise in global incidence of diabetes, particularly Type 1 diabetes, drives the demand for glucagon as it is a critical treatment for managing severe hypoglycemia. The International Diabetes Federation (2023) estimates that over 540 million adults live with diabetes globally, highlighting the importance of glucagon therapy. In addition, educational initiatives by healthcare organizations about hypoglycemia management have increased the adoption of glucagon products, particularly among diabetic patients at high risk for severe hypoglycemic episodes. Moreover, surge in geriatric population acts as the key driving force of the global market. With the aging global population, there is a growing number of individuals at risk for diabetes and related complications, driving the demand for glucagon products. A 2024 study published by the World Health Organization revealed that the number of aged individuals will increase from 1 billion in 2020 to 1.4 billion by 2030. Moreover, the number of individuals aging 80 years and older is estimated to reach 426 million by 2050. Furthermore, beyond its use in hypoglycemia, glucagon is increasingly employed in diagnostic imaging procedures (e.g., radiology and endoscopy) to relax the gastrointestinal tract, broadening its market scope. However, high cost of glucagon therapies, especially for newer formulations such as nasal glucagon, can be a significant barrier to access for patients, particularly in low-income regions or for those without sufficient healthcare coverage. The use of glucagon, especially in emergency settings, typically requires guidance from healthcare professionals for proper administration, which can further limit its use in situations where immediate access to medical help is unavailable. On the contrary, innovations such as prefilled syringes, auto-injectors, and nasal glucagon formulations enhance the ease of administration, making glucagon therapy more accessible and user-friendly for patients and caregivers. Such developments are anticipated to open new avenues for the expansion of the global market during the forecast period.

The global glucagon industry is segmented into type, application, distribution channel, and region. On the basis of type, the market is categorized into injectable glucagon and nasal glucagon. As per application, it is segregated into hypoglycemia and diagnostic aid. Depending on distribution channel, it is fragmented into hospital pharmacies, retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the injectable glucagon segment is expected to dominate the market from 2024 to 2033.

On the basis of application, the hypoglycemia segment is anticipated to exhibit the growth of the global market during the forecast period.

Depending on distribution channel, the hospital pharmacies segment is projected to grow at a notable pace throughout the forecast period.

Region wise, the glucagon market is likely to show strong growth in North America.

Competition Analysis

The major players operating in the global glucagon market include Novo Nordisk A/S, Fresenius SE & Co. KGaA, Amphastar Pharmaceuticals, Inc., Xeris Biopharma Holdings, Inc., ILS Inc, United Biotech (P) Limited, Zealand Pharma A/S, Taj Pharmaceuticals Limited, Eli Lilly and Company, and Pfizer Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Reimbursement Scenario

Key Market Segments

By Product Type

  • Injectable Glucagon
  • Nasal Glucagon

By Application

  • Hypoglycemia
  • Diagnostic Aid

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Novo Nordisk A/S
    • Fresenius SE & Co. KGaA
    • Amphastar Pharmaceuticals, Inc.
    • Xeris Biopharma Holdings, Inc.
    • ILS Inc
    • United Biotech (P) Limited
    • Zealand Pharma A/S
    • Taj Pharmaceuticals Limited
    • Eli Lilly and Company.
    • Pfizer Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: GLUCAGON MARKET, BY PRODUCT TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Product Type
  • 4.2. Injectable Glucagon
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Nasal Glucagon
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: GLUCAGON MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Hypoglycemia
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Diagnostic Aid
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: GLUCAGON MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Distribution Channel
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Retail Pharmacies
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Online Pharmacies
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: GLUCAGON MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Product Type
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By Distribution Channel
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Glucagon Market
      • 7.2.6.1. Market Size and Forecast, By Product Type
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By Distribution Channel
    • 7.2.7. Canada Glucagon Market
      • 7.2.7.1. Market Size and Forecast, By Product Type
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By Distribution Channel
    • 7.2.8. Mexico Glucagon Market
      • 7.2.8.1. Market Size and Forecast, By Product Type
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Product Type
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By Distribution Channel
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Glucagon Market
      • 7.3.6.1. Market Size and Forecast, By Product Type
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By Distribution Channel
    • 7.3.7. Germany Glucagon Market
      • 7.3.7.1. Market Size and Forecast, By Product Type
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By Distribution Channel
    • 7.3.8. Italy Glucagon Market
      • 7.3.8.1. Market Size and Forecast, By Product Type
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By Distribution Channel
    • 7.3.9. Spain Glucagon Market
      • 7.3.9.1. Market Size and Forecast, By Product Type
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By Distribution Channel
    • 7.3.10. UK Glucagon Market
      • 7.3.10.1. Market Size and Forecast, By Product Type
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By Distribution Channel
    • 7.3.11. Rest Of Europe Glucagon Market
      • 7.3.11.1. Market Size and Forecast, By Product Type
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Product Type
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By Distribution Channel
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Glucagon Market
      • 7.4.6.1. Market Size and Forecast, By Product Type
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By Distribution Channel
    • 7.4.7. Japan Glucagon Market
      • 7.4.7.1. Market Size and Forecast, By Product Type
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By Distribution Channel
    • 7.4.8. India Glucagon Market
      • 7.4.8.1. Market Size and Forecast, By Product Type
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By Distribution Channel
    • 7.4.9. South Korea Glucagon Market
      • 7.4.9.1. Market Size and Forecast, By Product Type
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By Distribution Channel
    • 7.4.10. Australia Glucagon Market
      • 7.4.10.1. Market Size and Forecast, By Product Type
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By Distribution Channel
    • 7.4.11. Rest of Asia-Pacific Glucagon Market
      • 7.4.11.1. Market Size and Forecast, By Product Type
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Product Type
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By Distribution Channel
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Glucagon Market
      • 7.5.6.1. Market Size and Forecast, By Product Type
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By Distribution Channel
    • 7.5.7. South Africa Glucagon Market
      • 7.5.7.1. Market Size and Forecast, By Product Type
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By Distribution Channel
    • 7.5.8. Saudi Arabia Glucagon Market
      • 7.5.8.1. Market Size and Forecast, By Product Type
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By Distribution Channel
    • 7.5.9. Rest of LAMEA Glucagon Market
      • 7.5.9.1. Market Size and Forecast, By Product Type
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping Of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Novo Nordisk A/S
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Fresenius SE And Co. KGaA
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Amphastar Pharmaceuticals, Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Xeris Biopharma Holdings, Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. ILS Inc
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. United Biotech (P) Limited
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Zealand Pharma A/S
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Taj Pharmaceuticals Limited
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Eli Lilly And Company.
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Pfizer Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments